DeGregorio Family Foundation’s Post

https://lnkd.in/gUb7vuZm Skin Tumors Important Question and Answers Question.1. Write short note on basal cell carcinoma. Question.2. Write short note on epithelioma. Question.3. Write short note on neurofibroma. Question.4. Describe features of mole turning into melanocarcinoma. Question.5. Write difference between squamous cell carcinoma and basal cell carcinoma. #basalcellcarcinoma #epithelioma #neurofibroma #melanocarcinoma #generalsurgery

Tumor markers are proteins released by neoplasm into circulation. Tumor markers should be used to confirm diagnosis, monitor therapeutic response, monitor tumor recurrence, but not as a usage of diagnosis alone without physical exam or biopsy. Common tumor markers include PSA (for prostate carcinoma), AFP (seen in hepatocellular carcinoma), and CA-125 (seen in ovarian and epithelial tumors). Learn more high yield-concepts about Tumor markers on our DAILY Medbullets Step 1 podcast. Listen wherever you listen to podcasts! https://bit.ly/47NErK0

Interested in expert-generated tumor segmentations? We recently added 4 datasets to https://lnkd.in/eudCiKrC which annotated 1) hepatoblastomas, 2) nasopharyngeal cancers, 3) desmoid tumors or aggressive fibromatosis, and 4) head-neck squamous cell carcinomas from NCI Clinical Trials.

Although much success has been achieved with #immunotherapy for treatment of blood cancers, its efficacy remains limited in solid tumors. In our latest scientific poster, we describe a method to assess the effectiveness of T-cell invasion in solid tumors using PDOs. To quantify T-cell invasion, we developed an image analysis method to measure the distance of each T-cell to the nearest organoid. Download the poster to read the results: https://bit.ly/4bXJHwp #CancerResearch #LabAutomation #HighThroughputScreening #3DBiology #DrugDevelopment

Our latest publication (and first primary radiological paper) having a look at PET CT as a predictor of patient outcomes in anal cancer. Give it a look if you’re interested! https://lnkd.in/gRcHExv7

Rosario Ligresti MD FASGE Building on the discussion about indeterminate strictures, I wanted to share a case where EUS-FNB provided a diagnosis that brushings did not. The patient sought a second opinion at a renowned medical facility, which took four months to secure. The surgeon there performed a PET-CT scan and concluded that the patient had pancreatic cancer rather than cholangiocarcinoma. This was based on the PET-CT report of a 2 cm hypodense mass near the metal stent I had placed following the tissue diagnosis. However, they did not review the initial CT and MRI, which both showed no masses; only the EUS had provided the correct diagnosis. Given the differing chemotherapy regimens, relying solely on imaging in such nuanced cases may not yield the best therapeutic options for the patient. I do not think that any experienced endosonographer, looking at the image below, where the needle is clearly in the distal CBD wall, yielding adenocarcinoma, would conclude that this is a pancreatic cancer. Mohammad Al Haddad, MD, MSc Nauzer Forbes

Our latest study, published in the Journal of Clinical Case Reports and Images, delves into the rare and aggressive subtype of prostate cancer: Pure Small Cell Carcinoma. 🦠 This peer-reviewed open access paper sheds light on the clinical and pathological aspects of this condition, focusing on a 73-year-old male patient who presented with acute urinary retention. Despite a normal digital rectal examination and a PSA value of 1.81 ng/dl, further investigation revealed a prostate size of 101 cc and the presence of pure small cell carcinoma. 🩺 Following an open prostatectomy, the patient underwent four cycles of etoposide and cisplatin chemotherapy. However, despite treatment efforts, the patient sadly passed away 13 months after the initial diagnosis. Our study meticulously evaluates both the pathological and clinical findings of small cell carcinoma of the prostate, offering valuable insights into this challenging condition. 📝 For more details on this rare case report and its implications, check out the full article here: https://lnkd.in/gRNbjBzz #ProstateCancer #Research #ClinicalCaseReports #MedicalScience #OpenAccess #PeerReviewed #Healthcare #Medicine

🔊Today we share the #Review "Circulating Tumor DNA Methylation Biomarkers for Characterization and Determination of the Cancer Origin in Malignant Liver Tumors" 👏by Tina Draškovič et al. University of Ljubljana Find more here⏭️ https://lnkd.in/diyWVwCn Keywords: malignant liver tumors; primary malignant liver tumors; liver metastases; liquid biopsy; cell-free DNA; circulating tumor DNA; tissue of origin determination; DNA methylation

Synaptophysin is a glycoprotein (38KD), localized to presynaptic neurosecretory vesicles, such as synaptic vesicle membrane, cytoplasmic vesicles, secretory vesicles, and synaptosome, in the brain and endocrine cells, including islets cells in the pancreas. Pancreatic islets cells are usually used for positive control and as cytoplasmic staining for immunohistochemistry testing. Synaptophysin expression is often seen in well-differentiated neuroendocrine tumor (carcinoid tumor), neuroendocrine carcinoma, neuroblastoma, adrenal cortical tumors, paraganglioma, pheochromocytoma, Merkel cell carcinoma, parathyroid tumor, and medullary thyroid carcinoma. Synaptophysin has been frequently used in conjunction with chromogranin A, INSM1 and CD56 for the identification of neuroendocrine tumors. #antibodies https://lnkd.in/gTeZwE6Y

Phase 1 study of this novel dual-targeting CAR T-cell therapy (named CARv3-TEAM-E) in three patients with EGFR-expressing glioblastoma has demonstrated the potential of CAR T-cell therapy to shrink aggressive brain tumors. https://lnkd.in/g62aWcxK